IL-17A Neutralization Prevents Immune Checkpoint Inhibitor-Associated Myocarditis and Synergistically Enhances Immune Checkpoint Blockade Therapy

ABSTRACT: Immune checkpoint inhibitor (ICI)-associated myocarditis is a severe and often fatal immune-related adverse event observed in cancer immunotherapy. To investigate its pathogenesis and prevention, we performed spatial transcriptomics on cardiac tissue from mice treated with dual ICIs (anti–PD-1 and anti–CTLA-4) with or without IL-17A neutralizing antibody. Our analysis revealed immune-mediated fibrotic remodeling and distinct spatial immune cell distributions, providing insights into how IL-17A blockade mitigates cardiac toxicity without compromising immune activation.

ORGANISM(S): Mus musculus

PROVIDER: GSE297745 | GEO | 2026/04/28

REPOSITORIES: GEO